CGEM — Cullinan Therapeutics, Inc.

CGEM closed at $14.54 (+1.18%) on Oct 26, 2026. Active automatic shelf (S-3ASR, Apr 2026); dilution risk: low. Float: 53.5M shares. Latest SEC filing: 8-K on Oct 2, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for CGEM in the TickerWise workspace.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Company profile

• Sector: Healthcare
• Industry: Medical - Pharmaceuticals
• Country: US
• Exchange: NASDAQ
• Employees: 111
• Website: https://cullinantherapeutics.com

Latest SEC filings for CGEM

• 2026-10-028-K
• 2026-09-248-K
• 2026-09-148-K
• 2026-08-138-K
• 2026-08-07SCHEDULE 13G
• 2026-08-068-K
• 2026-08-0610-Q
• 2026-06-168-K
• 2026-06-108-K
• 2026-06-088-K

Latest CGEM news

• 2026-10-08Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia Read article
• 2026-09-29Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases Read article
• 2026-09-28Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 Read article

Related companies

• ONC — BeOne Medicines Ltd.
• LQDA — Liquidia Corporation
• DFTX — Definium Therapeutics, Inc.
• AVLN — Avalyn Pharma Inc. Common Stock
• LTGO — Latigo Biotherapeutics Inc.
• LFMDP — LifeMD, Inc.
• CUVL — Clinuvel Pharmaceuticals Ltd.
• ETRA — Electra Therapeutics Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.